Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study

This study comprises 3 stages:

1. Collection of tumor and blood samples. 2. Creation of organoid models based on tumor samples. 3. Development of functional tests to predict clinical response to treatment.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Endometrial Cancer Endometrial Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Diseases Uterine Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Centre François Baclesse

Caen, France

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient aged 18 years or more
Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.
Patient with localized endometrial cancer, presenting:

A high-grade endometrioid histological type and/or
P53 mutation and/or
a non-endometrioid histological type regardless of P53 status.
Patient affiliated to a social security scheme
Information and signature of informed consent prior to any specific study procedure

Exclusion criteria

Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).
Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.

Treatment and study plan

tumour and blood samples

Other

Tumour and blood samples

Primary outcomes

Rate of establishment of exploitable tumor organoid lines

Time frame: through study completion, an average of 3 years

Rate of establishment of tumor organoid lines usable for predictive assays of response to PARP inhibitors.

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

Centre Francois Baclesse

Other

Registry information

Acronym: PENDOR

Important dates

Study start: 2024
Primary completion: 2027
Study completion: 2027
First posted: Sep 19, 2024
Registry last updated: Nov 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting